November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023 Read more
November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari-september 2023 Read more
November 21, 2023 Regulatory InDex Pharmaceuticals discontinues cobitolimod phase III program Read more
November 21, 2023 Regulatory InDex Pharmaceuticals avbryter fas III-programmet med cobitolimod Read more
November 21, 2023 Regulatory InDex Pharmaceuticals avbryter fas III-programmet med cobitolimod Read more
October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting Read more
October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2024 Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals har beviljats ett nytt patent för cobitolimod i Sydkorea Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals meddelar att alla patienter som krävs för att nå milstolpen för dosvalet av cobitolimod har slutfört Induktionsstudie 1 av fas III-programmet CONCLUDE Read more
October 5, 2023 Non Regulatory InDex Pharmaceuticals deltar vid United European Gastroenterology Week 2023 Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023 Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2023 Read more
August 22, 2023 Non Regulatory ”Positive results from PK study with cobitolimod” selected as one of the best abstracts for poster presentation at UEGW Read more
August 22, 2023 Non Regulatory ”Positiva resultat från PK-studie med cobitolimod” utsedd till en av de bästa abstrakten för posterpresentation vid UEGW Read more
August 2, 2023 Regulatory InDex Pharmaceuticals has been granted a new patent in Europe for the commercial formulation of cobitolimod Read more
August 2, 2023 Regulatory InDex Pharmaceuticals har beviljats ett nytt patent i Europa för den kommersiella formuleringen av cobitolimod Read more
May 31, 2023 Non Regulatory InDex Pharmaceuticals investeraruppdatering 1 juni kl. 15:00 CET Read more
May 31, 2023 Non Regulatory InDex Pharmaceuticals investeraruppdatering 1 juni kl. 15:00 CET Read more
May 31, 2023 Regulatory InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan Read more
May 31, 2023 Regulatory InDex Pharmaceuticals och Viatris Japan ingår licensavtal för att utveckla och kommersialisera cobitolimod i Japan Read more
May 24, 2023 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 24, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2023 Read more
May 24, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2023 Read more
April 26, 2023 Non Regulatory Welcome to an InDex Pharmaceuticals business update presentation in Stockholm on May 9, from 13:00 to 15.30 CET Read more
April 26, 2023 Non Regulatory Välkommen till InDex Pharmaceuticals Business Update-presentation i Stockholm den 9 maj, kl 13:00 till 15.30 CET Read more
April 19, 2023 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 12, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2022 Read more
April 12, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2022 Read more
March 15, 2023 Non Regulatory InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod Read more
March 15, 2023 Non Regulatory InDex Pharmaceuticals meddelar positiva resultat från en farmakokinetikstudie (PK-studie) med cobitolimod Read more
February 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2022 Read more
February 14, 2023 Non Regulatory InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod Read more
February 14, 2023 Non Regulatory InDex Pharmaceuticals tillhandahåller kompletterande information om fas III-programmet CONCLUDE med cobitolimod Read more
January 27, 2023 Regulatory InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod Read more
January 27, 2023 Regulatory InDex Pharmaceuticals uppdaterar tidplanen för fas III-studien CONCLUDE med cobitolimod Read more